Deletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD)

Mayo Clinic experience

Rama Nanah, Darci Zblewski, Mrinal M Patnaik, Kebede Begna, Rhett Ketterling, Vivek N. Iyer, William Hogan, Mark R Litzow, Aref Al-Kali

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A variety of interstitial Lung Diseases (ILD) have been described in patients with myelodysplastic syndromes (MDS) with possible etiologies including autoimmunity, drug related toxicity, and recurrent infections. A comprehensive study of ILD in MDS patients has not been previously performed. Out of 827 consecutive biopsy proven MDS patients seen at our institution from June 1970–May 2010, 18 (2%) were found to have ILD. There was no statistical significance in baseline characteristics between patients with ILD (ILD +) vs those without ILD (ILD−). Cytogenetic studies were reported in 14 ILD + patients out of whom 43% had 5q- abnormalities (21% isolated and 22% part of complex karyotype). Prevalence of high risk MDS was similar between both groups (22% vs 29% in ILD−) with similar overall survival. ILD was diagnosed prior to MDS in the majority of cases (72%) with a median time to MDS diagnosis of 22.3 months. Our study suggests that ILD are present in a higher percentage than anticipated in the MDS population. Deletion 5q was frequent in ILD+ cases and this requires further study. Prior MDS treatment and autoimmunity seemed to play no significant role in ILD development.

Original languageEnglish (US)
Pages (from-to)112-115
Number of pages4
JournalLeukemia Research
Volume50
DOIs
StatePublished - Nov 1 2016

Fingerprint

Myelodysplastic Syndromes
Interstitial Lung Diseases
Autoimmunity
Drug-Related Side Effects and Adverse Reactions
Karyotype
Cytogenetics

Keywords

  • Azacitidine
  • Hypomethylating agents
  • Interstitial lung disease
  • Lenalidomide
  • Myelodysplastic syndrome

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Deletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD) : Mayo Clinic experience. / Nanah, Rama; Zblewski, Darci; Patnaik, Mrinal M; Begna, Kebede; Ketterling, Rhett; Iyer, Vivek N.; Hogan, William; Litzow, Mark R; Al-Kali, Aref.

In: Leukemia Research, Vol. 50, 01.11.2016, p. 112-115.

Research output: Contribution to journalArticle

@article{0cece9fdfc104d7094ca18cf3ba474dd,
title = "Deletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD): Mayo Clinic experience",
abstract = "A variety of interstitial Lung Diseases (ILD) have been described in patients with myelodysplastic syndromes (MDS) with possible etiologies including autoimmunity, drug related toxicity, and recurrent infections. A comprehensive study of ILD in MDS patients has not been previously performed. Out of 827 consecutive biopsy proven MDS patients seen at our institution from June 1970–May 2010, 18 (2{\%}) were found to have ILD. There was no statistical significance in baseline characteristics between patients with ILD (ILD +) vs those without ILD (ILD−). Cytogenetic studies were reported in 14 ILD + patients out of whom 43{\%} had 5q- abnormalities (21{\%} isolated and 22{\%} part of complex karyotype). Prevalence of high risk MDS was similar between both groups (22{\%} vs 29{\%} in ILD−) with similar overall survival. ILD was diagnosed prior to MDS in the majority of cases (72{\%}) with a median time to MDS diagnosis of 22.3 months. Our study suggests that ILD are present in a higher percentage than anticipated in the MDS population. Deletion 5q was frequent in ILD+ cases and this requires further study. Prior MDS treatment and autoimmunity seemed to play no significant role in ILD development.",
keywords = "Azacitidine, Hypomethylating agents, Interstitial lung disease, Lenalidomide, Myelodysplastic syndrome",
author = "Rama Nanah and Darci Zblewski and Patnaik, {Mrinal M} and Kebede Begna and Rhett Ketterling and Iyer, {Vivek N.} and William Hogan and Litzow, {Mark R} and Aref Al-Kali",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.leukres.2016.10.002",
language = "English (US)",
volume = "50",
pages = "112--115",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Deletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD)

T2 - Mayo Clinic experience

AU - Nanah, Rama

AU - Zblewski, Darci

AU - Patnaik, Mrinal M

AU - Begna, Kebede

AU - Ketterling, Rhett

AU - Iyer, Vivek N.

AU - Hogan, William

AU - Litzow, Mark R

AU - Al-Kali, Aref

PY - 2016/11/1

Y1 - 2016/11/1

N2 - A variety of interstitial Lung Diseases (ILD) have been described in patients with myelodysplastic syndromes (MDS) with possible etiologies including autoimmunity, drug related toxicity, and recurrent infections. A comprehensive study of ILD in MDS patients has not been previously performed. Out of 827 consecutive biopsy proven MDS patients seen at our institution from June 1970–May 2010, 18 (2%) were found to have ILD. There was no statistical significance in baseline characteristics between patients with ILD (ILD +) vs those without ILD (ILD−). Cytogenetic studies were reported in 14 ILD + patients out of whom 43% had 5q- abnormalities (21% isolated and 22% part of complex karyotype). Prevalence of high risk MDS was similar between both groups (22% vs 29% in ILD−) with similar overall survival. ILD was diagnosed prior to MDS in the majority of cases (72%) with a median time to MDS diagnosis of 22.3 months. Our study suggests that ILD are present in a higher percentage than anticipated in the MDS population. Deletion 5q was frequent in ILD+ cases and this requires further study. Prior MDS treatment and autoimmunity seemed to play no significant role in ILD development.

AB - A variety of interstitial Lung Diseases (ILD) have been described in patients with myelodysplastic syndromes (MDS) with possible etiologies including autoimmunity, drug related toxicity, and recurrent infections. A comprehensive study of ILD in MDS patients has not been previously performed. Out of 827 consecutive biopsy proven MDS patients seen at our institution from June 1970–May 2010, 18 (2%) were found to have ILD. There was no statistical significance in baseline characteristics between patients with ILD (ILD +) vs those without ILD (ILD−). Cytogenetic studies were reported in 14 ILD + patients out of whom 43% had 5q- abnormalities (21% isolated and 22% part of complex karyotype). Prevalence of high risk MDS was similar between both groups (22% vs 29% in ILD−) with similar overall survival. ILD was diagnosed prior to MDS in the majority of cases (72%) with a median time to MDS diagnosis of 22.3 months. Our study suggests that ILD are present in a higher percentage than anticipated in the MDS population. Deletion 5q was frequent in ILD+ cases and this requires further study. Prior MDS treatment and autoimmunity seemed to play no significant role in ILD development.

KW - Azacitidine

KW - Hypomethylating agents

KW - Interstitial lung disease

KW - Lenalidomide

KW - Myelodysplastic syndrome

UR - http://www.scopus.com/inward/record.url?scp=84990946297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990946297&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2016.10.002

DO - 10.1016/j.leukres.2016.10.002

M3 - Article

VL - 50

SP - 112

EP - 115

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

ER -